-- LPL Financial (LPLA) has an average rating of overweight and mean price target of $403, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $320.57, Change: $-13.56, Percent Change: -4.06%
Cboe Global Markets (CBOE) said Friday it is reducing its workforce by about 20%.Price: $324.55, Change: $+24.46, Percent Change: +8.15%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:DINO delivered exceptional Q1 results with adjusted EPS of $0.69 vs. a consensus loss of $0.27, beating by $0.74, while adjusted EBITDA more than doubled to $426M from $201M. The refining segment led the recovery with $514M operating income vs. a$30M loss in the prior year, though regional performance diverged with West margins expanding to $14.61/barrel while Mid-Continent compressed to $3.58/barrel. We believe the strong performance reflects improving refining fundamentals and regulatory tailwinds in renewables. The renewables segment returned to profitability with $182M operating income, benefiting from higher volumes, improved margins, and $49M in prior-year Producer Tax Credit benefits. Cash generation remained robust at $457M from operations, more than covering $167M in shareholder returns, while the balance sheet strengthened with cash rising to $1.15B. We expect continued benefit from favorable renewable diesel demand dynamics and small refinery RINs waivers.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $235 from $220 following Q1, valuing shares at 26x our 2027 EPS outlook of $9.04 (up from $8.99; 2026 EPS view revised to $8.50 from $8.28). IEX posted a robust Q1, with operating EPS of $2.00 rising 14% Y/Y and exceeding consensus by $0.23, propelled by standout performance in Health & Science Tech. Organic sales growth accelerated to 5% Y/Y from 1% in Q4, while orders hit a record $988M (up 10% Y/Y), signaling broadened demand. Health & Science Tech was the clear growth engine, delivering 11% organic sales growth alongside 100-bp adjusted EBITDA margin expansion to 26.6%. This strength was fueled by AI-driven demand for data center power solutions, semiconductor applications, and space & defense markets. Despite gross margin compression of 40 bps, adjusted EBITDA margin expanded 50 bps to 26%, suggesting the company's 80/20 initiatives are gaining traction.Overall, Q1 results were encouraging and contributed to our raised growth outlook for the year.